The nation of Zimbabwe has declined a significant US healthcare agreement worth $367m (£272m) spanning five years due to Washington's request for sensitive data.
The decision became public after a government memo dated December was disclosed, which showed President Emmerson Mnangagwa felt the deal was "lopsided".
An official representative has since explained that the US was seeking genetic material for research and profit but was unwilling to share the resulting advantages from future treatments.
"We are forced to start the difficult and regrettable task of winding down our health assistance in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had furnished over $1.9bn as health assistance to Zimbabwe during the past twenty years.
A doctors' association in Zimbabwe has appealed for further dialogue to reach a agreement acceptable to all parties so the country's vital HIV programme can continue.
Wider Context
This development follows a comparable situation in Kenya, where a high court halted a related health funding agreement after concerns were filed about the safety of Kenyans' health data.
Since returning to office recently, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had overseen assistance for the US government, but Trump claimed its spending was "inefficient" and his government was seeking government-to-government agreements to enhance openness and accountability.
As per statements, 16 African countries have to date signed similar agreements, representing more than $18.3bn in new funding.
Specifics of the Declined Agreement
The money for Zimbabwe would have funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving HIV treatment via US-supported initiatives," the Ambassador added.
However, official spokesman Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to surrender its biological resources and data for a long time, without any corresponding promise of access to any scientific breakthroughs – like new medicines or tests – that might result from that provided information," his statement read.
"Put simply, our nation would supply the raw materials for scientific discovery without any assurance that the final treatments would be available to our population should a new pandemic emerge."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of bilateral deals were upending structures previously established through the international organization.
The spokesperson cited its Pandemic Benefit-Sharing framework created to deal with potential pandemics.
"This framework is intended to ensure that when a nation contributes its samples, the resulting advantages – including vaccines and treatments – are shared equitably, not commercialised exclusively by those with the resources to develop them."
These objections over the US deal "must not be interpreted as hostility towards the US," he added.
"We welcome continued discussions with our US partners on how future co-operation might be designed in a manner that honours the sovereignty and interests of each country."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) stated it recognised the official position, but suggested that negotiations must proceed since a large portion of the country's HIV programmes were funded by foreign aid.
"In cases where technical issues exist, such as those relating to information security or agreement terms, these can frequently be addressed via technical clarification and negotiated safeguards," it said.
The situation emphasises the ongoing challenges between receiving vital foreign assistance and safeguarding national sovereignty in an increasingly data-driven world.